First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status.
European Journal of Cancer(2020)
摘要
•Evidence on first-line pembrolizumab in Eastern Cooperative Oncology Group performance status (PS) 2 non–small cell lung cancer (NSCLC) (PD-L1 ≥ 50%) are poor.•This retrospective study documented dismal outcomes in this population of interest.•Patients with disease burden-determined poor PS had poor prognosis.•Comorbidity-induced PS 2 may still benefit form pembrolizumab.•The differential determinants of PS 2 in NSCLC are relevant for clinical decisions.
更多查看译文
关键词
NSCLC,Immunotherapy,Immune checkpoint inhibitors,PD-1,ECOG PS 2
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络